{
    "root": "909bac1c-3936-4bf5-bcda-eebc8a0e24ee",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Famotidine",
    "value": "20250509",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        },
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        }
    ],
    "indications": {
        "text": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : \u2022 active duodenal ulcer ( du ) . \u2022 active gastric ulcer ( gu ) . \u2022 symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . \u2022 erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : \u2022 treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . \u2022 reduction risk duodenal ulcer recurrence .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "zollinger-ellison syndrome (DOID:0050782)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050782"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "zollinger-ellison syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_913"
            }
        ]
    },
    "contraindications": {
        "text": "indication recommended ( ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastric ulcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; 40 mg twice daily adults pathological hypersecretory conditions 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du recurrence 20 mg daily \u2022 full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( , ) ( ) : \u2022 take daily bedtime twice daily morning bedtime without food .",
        "doid_entities": [
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "famotidine tablets usp , 40 mg , white , round , biconvex , film-coated tablets debossed \u201c \u201d one side \u201c 12 \u201d side . supplied follows : bottles 14 ndc 68788-8733-4 bottles 30 ndc 68788-8733-3 bottles 60 ndc 68788-8733-6 bottles 90 ndc 68788-8733-9 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense usp tight , light-resistant container .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h 2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:              \u2022\u00a0active duodenal ulcer (DU).              \u2022\u00a0active gastric ulcer (GU).              \u2022\u00a0symptomatic nonerosive gastroesophageal reflux disease (GERD).              \u2022\u00a0erosive esophagitis due to GERD, diagnosed by biopsy.          \n                  Famotidine tablets are indicated in adults for the:              \u2022\u00a0treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).              \u2022\u00a0reduction of the risk of duodenal ulcer recurrence.",
    "contraindications_original": "Indication Recommended Dosage (                          ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily \u2022\u00a0See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (                 ,                  ) Administration ( ): \u2022\u00a0Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions_original": "Famotidine Tablets USP, 40 mg, are white, round, biconvex, film-coated tablets debossed with \u201cT\u201d on one side and \u201c12\u201d on the other side. They are supplied as follows:          \n                   Bottles of 14\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 NDC 68788-8733-4    \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 NDC 68788-8733-3    \n                  Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 NDC 68788-8733-6       \n                  Bottles of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 NDC 68788-8733-9    \n                  \n                  \n                     Storage\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H             2) receptor antagonists.",
    "drug": [
        {
            "name": "Famotidine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        }
    ]
}